Company News
ArriVent Announces 44.8% ORR in Phase 1
ArriVent BioPharma reported Phase 1 data for antibody‑drug conjugate ARR‑217 in gastrointestinal cancers, treating 123 patients up to Aug 5 2026.
At the 6 mg/kg dose, the study achieved a 44.8% object
